Printer Friendly

Novacap to acquire PCI Synthesis.

M2 PHARMA-June 22, 2018-Novacap to acquire PCI Synthesis

(C)2018 M2 COMMUNICATIONS

Canada-based pharmaceutical synthesis company, Novacap, has agreed to acquire Boston-based PCI Synthesis, a pharmaceutical contract development and manufacturing organisation (CDMO), it was reported yesterday.

Financial details of the deal were not revealed. The transaction is subject to customary merger control approval. BlackArch Partners served as the exclusive financial advisor to PCI Synthesis.

Combined, the two firms will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap's global position in pharmaceutical synthesis with 12 cGMP sites, two main R&D centres and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 22, 2018
Words:122
Previous Article:PharmaEngine announces encouraging topline results from global pivotal trial of PEP503 in soft tissue sarcoma.
Next Article:Novo Nordisk reports success in two Semaglutide phase 3a trials.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters